Remus Pharmaceuticals (NSE:REMUS) Cash, Cash Equivalents, Marketable Securities : ₹460 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Remus Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Remus Pharmaceuticals's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (₹422.79 Mil) to Mar. 2024 (₹72.02 Mil) but then increased from Mar. 2024 (₹72.02 Mil) to Sep. 2024 (₹459.93 Mil).

Remus Pharmaceuticals's annual cash, cash equivalents, marketable securities increased from Mar. 2021 (₹8.31 Mil) to Mar. 2022 (₹11.49 Mil) and increased from Mar. 2022 (₹11.49 Mil) to Mar. 2024 (₹72.02 Mil).

Remus Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Remus Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remus Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Remus Pharmaceuticals Annual Data

Trend

Mar20

Mar21

Mar22

Mar24

Cash, Cash Equivalents, Marketable Securities

11.98

8.31

11.49

72.02

Remus Pharmaceuticals Semi-Annual Data
	Mar20	Mar21	Mar22	Sep23	Mar24	Sep24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			8.31	11.49	422.79	72.02	459.93

Remus Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Remus Pharmaceuticals (NSE:REMUS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Remus Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Remus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054

Website

https://www.remuspharma.com

Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.

Remus Pharmaceuticals Headlines

No Headlines